CGON CG Oncology: Enterprise Value-to-Revenue Multiple

CG Oncology (CGON) - corporate logo

The ultra-stable external biopharmaceutical environment minimizes the impact of sanctions on CG Oncology, Inc. (CGON). This EV/Sales multiple chart illustrates the business value-to-revenue trend, where the current level is 1027552.67. Strong pricing power in bladder cancer therapy ensures stability, although the company's success is critically dependent on the outcomes of highly specialized clinical trials and innovation expenditures.

CGON: CG Oncology, Inc. EV/Sales Multiple 11/23/2025 - 11/20/2026

CGON (CG Oncology Corp): analytical breakdowns and indicator data

- current price and projected stock value:
- cash and cash flow indicators:
Initial company analysis:CGON, CG Oncology, Inc.
Core merchandise of CG Oncology Inc

CG Oncology, Inc. (CGON) developments in oncolytic viruses and its patent protection create high added value, which is reflected in the EV-to-revenue dynamics. This indicator compares the total enterprise value, including debt and cash, with sales volume, allowing investors to assess the market premium relative to current cash flows and promptly identify risks of asset undervaluation or overbought conditions.

Competitor analysis for CG Oncology, Inc.

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Enterprise Value-to-Revenue Multiple UroGen Pharma Corp URGN|EV/Sales Multiple BCAX|Personalis, Inc. - Company Value to Revenue Ratio|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio